Literature DB >> 19105568

Lynch syndrome and related familial colorectal cancers.

Wael M Abdel-Rahman1, Päivi Peltomäki.   

Abstract

Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) refers to autosomal dominant predisposition to colorectal, endometrial, and a spectrum of other cancers. The syndrome is due to heterozygous germ line mutations in one of the mismatch repair genes MLH1, MSH2, MSH6, and PMS2. Amsterdam I and II criteria for clinical diagnosis and Bethesda guidelines for molecular testing of suspected patients usually point out additional families in which there is no evidence of mismatch repair deficiency even after screening by microsatellite instability analysis and/or immunohistochemistry for mismatch repair proteins. Hence, the term "Lynch syndrome" should be restricted to those families with germ line mutations in one of the mismatch repair genes. Familial colorectal tumors with no evidence of mismatch repair deficiency were shown to be clinically and molecularly distinct from classical Lynch syndrome tumors and, therefore, were designated "familial colorectal cancer type X" (FCC-X). The predisposing gene(s) to FCC-X is as yet unknown, but extensive research is currently underway to delineate its etiology. Given the above distinctions, the term hereditary nonpolyposis colorectal cancer (HNPCC), which was formerly used to refer to clinically diagnosed colorectal cancer families that might or might not have mismatch repair deficiency, is being replaced by one of the more informative names: Lynch syndrome and FCC-X.

Entities:  

Mesh:

Year:  2008        PMID: 19105568     DOI: 10.1615/critrevoncog.v14.i1.10

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  17 in total

Review 1.  Cancer models in Caenorhabditis elegans.

Authors:  Natalia V Kirienko; Kumaran Mani; David S Fay
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

Review 2.  Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications.

Authors:  Sara C Shalin; Stephen Lyle; Eduardo Calonje; Alexander J F Lazar
Journal:  Histopathology       Date:  2010-01       Impact factor: 5.087

Review 3.  Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model.

Authors:  Henry T Lynch; Jane F Lynch; Thomas A Attard
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

4.  p53 staining correlates with tumor type and location in sebaceous neoplasms.

Authors:  Sara C Shalin; Aniket Sakharpe; Stephen Lyle; Dina Lev; Eduardo Calonje; Alexander J Lazar
Journal:  Am J Dermatopathol       Date:  2012-04       Impact factor: 1.533

5.  Familial colorectal cancer: eleven years of data from a registry program in Switzerland.

Authors:  Michal Kovac; Endre Laczko; Ritva Haider; Josef Jiricny; Hansjakob Mueller; Karl Heinimann; Giancarlo Marra
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

6.  Debate about TGFBR1 and the susceptibility to colorectal cancer.

Authors:  Laura Valle
Journal:  World J Gastrointest Oncol       Date:  2012-01-15

Review 7.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

8.  Detection of DNA repair protein in colorectal cancer of patients up to 50 years old can increase the identification of Lynch syndrome?

Authors:  Demétrius Eduardo Germini; Ana Maria Amaral Antônio Mader; Luiz Guilherme Lisboa Gomes; Thérèse Rachel Teodoro; Maria Isete Fares Franco; Jaques Waisberg
Journal:  Tumour Biol       Date:  2015-09-25

Review 9.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications.

Authors:  H T Lynch; P M Lynch; S J Lanspa; C L Snyder; J F Lynch; C R Boland
Journal:  Clin Genet       Date:  2009-07       Impact factor: 4.438

10.  Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.

Authors:  Silvia Liliana Cossio; Patricia Koehler-Santos; Suzana Arenhart Pessini; Heleuza Mónego; Maria Isabel Edelweiss; Luise Meurer; Abdellatif Errami; Jordy Coffa; Hugo Bock; Maria Luiza Saraiva-Pereira; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.